COMMUNIQUÉS West-GlobeNewswire

Vaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ET
01/05/2026
Company to report first quarter 2026 financial results on May 7 SOUTH SAN FRANCISCO, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) today announced that members of the Company’s senior management [...]
Health Catalyst to Announce First Quarter 2026 Operating Results and Host Conference Call on Monday, May 11, 2026
01/05/2026
SALT LAKE CITY, May 01, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, will release [...]
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
01/05/2026
FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) [...]
InVitria Showcases Exbumin® and Optibumin® 25 at IPEC Excipient World: Biologics Summit: Recombinant Human Serum Albumins Already Used in On-Market Approved Biologics
01/05/2026
JUNCTION CITY, Kan., May 01, 2026 (GLOBE NEWSWIRE) -- InVitria, a global leader in chemically defined, animal-origin-free recombinant proteins for biologics manufacturing, announced its participation in the IPEC [...]
Weight Watchers Expands Med+ With Access to New Ozempic® pill (semaglutide)
01/05/2026
The addition of Ozempic® pill will give Weight Watchers Med+ members a new FDA-approved oral GLP-1 option for adults living with type 2 diabetes NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ [...]
Pelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026
01/05/2026
Company to hold a conference call at 8:30 a.m. ET DURHAM, N.C., May 01, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative [...]
IRADIMED CORPORATION Reports First Quarter 2026 Financial Results
01/05/2026
Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance Reports revenue of $22.0 million for the first quarter of 2026, an increase of $2.5 million, or 13%, [...]
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/05/2026
CLEVELAND, May 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in [...]
Breaking the Silence: Bladder Cancer Awareness Month Begins
01/05/2026
BCAN leads nationwide effort to drive earlier detection and open conversations Bethesda, MD, May 01, 2026 (GLOBE NEWSWIRE) -- The Bladder Cancer Advocacy Network (BCAN) today marks the beginning of Bladder Cancer [...]
Specialty Nutrition Names Alejandra Gratson Managing Partner, Strengthening Innovation and Commercialization Leadership
01/05/2026
LIGHTHOUSE POINT, Fla., May 01, 2026 (GLOBE NEWSWIRE) -- Specialty Nutrition has named Alejandra Gratson, PhD , managing partner, expanding its leadership in nutrition innovation and commercialization strategy. Gratson [...]
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
01/05/2026
ZUG, Switzerland, May 01, 2026 (GLOBE NEWSWIRE) -- Latest findings from the DME AWARE Delphi Study on unmet needs in diabetic macular edema (DME) management highlighting the need for non-invasive therapeutic options to [...]
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
01/05/2026
Latest findings from the DME AWARE Delphi Study on unmet needs in diabetic macular edema (DME) management highlighting the need for non-invasive therapeutic options to be presented by Baruch Kuppermann, M.D., Ph.D. New [...]
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2026
01/05/2026
Tokyo, Japan and Cambridge, UK, 1 May 202 6 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March [...]
Senseonics Announces Pricing of $80 Million Public Offering of Common Stock and Pre-Funded Warrants
01/05/2026
GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable [...]
MemoPryl Under Investigation (2026 Official Website Scam WARNING Update) Avoid Fake Complaints & Hidden Risks
01/05/2026
MemoPryl Scam Warning Explained: Nootropic Ingredients, Official Website Pricing, and 60-Day Refund Policy — 2026 Consumer Verification Update Aurora, CO, April 30, 2026 (GLOBE NEWSWIRE) -- These statements have not [...]
YD Bio Limited Reports Full Year 2025 Financial Results
01/05/2026
TAIPEI, Taiwan, April 30, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic [...]
Totus Medicines to Present Interim Phase 1b Clinical Data for TOS-358 + Fulvestrant Doublet Therapy in HR+/HER- Breast Cancer Patients at ESMO Breast Cancer Annual Congress 2026
01/05/2026
TOS-358 is a covalent, pan-mutant, α-specific PI3K inhibitor designed to address key limitations of existing PI3Kα therapies which include limited mutation coverage and poor tolerability Data will include efficacy, [...]
InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow
01/05/2026
The Company reported over NIS 270 million in revenue, NIS 37 million in Net loss, NIS 47 million in Adjusted EBITDA and NIS 17 million in positive operating cash flow, reflecting strong resilience and consistent [...]
Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering
01/05/2026
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of [...]

Pages